Elizabeth A. Kuczynski

1.7k total citations · 1 hit paper
16 papers, 1.1k citations indexed

About

Elizabeth A. Kuczynski is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Elizabeth A. Kuczynski has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Elizabeth A. Kuczynski's work include Angiogenesis and VEGF in Cancer (7 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Mechanisms and Therapy (3 papers). Elizabeth A. Kuczynski is often cited by papers focused on Angiogenesis and VEGF in Cancer (7 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Mechanisms and Therapy (3 papers). Elizabeth A. Kuczynski collaborates with scholars based in Canada, United Kingdom and Belgium. Elizabeth A. Kuczynski's co-authors include Robert S. Kerbel, Andrew R. Reynolds, Peter Vermeulen, Francesco Pezzella, Daniel J. Sargent, Axel Grothey, Shan Man, Christina R. Lee, Brenda L. Coomber and Eric X. Chen and has published in prestigious journals such as Nature reviews. Cancer, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Elizabeth A. Kuczynski

16 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vessel co-option in cancer

2019 311 citations Elizabeth A. Kuczynski, Peter Vermeulen et al. Nature Reviews Clinical Oncology profile →

Peers

Countries citing papers authored by Elizabeth A. Kuczynski

Since Specialization

Citations

This map shows the geographic impact of Elizabeth A. Kuczynski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth A. Kuczynski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth A. Kuczynski more than expected).

Fields of papers citing papers by Elizabeth A. Kuczynski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth A. Kuczynski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth A. Kuczynski. The network helps show where Elizabeth A. Kuczynski may publish in the future.

Co-authorship network of co-authors of Elizabeth A. Kuczynski

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth A. Kuczynski. A scholar is included among the top collaborators of Elizabeth A. Kuczynski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth A. Kuczynski. Elizabeth A. Kuczynski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Longitudinal tracking of T cell lymphomas in mice using flow cytometry 2023 ·STAR Protocols ·Elizabeth A. Kuczynski, Larissa S. Carnevalli, Charles Sinclair	2
2	A preclinical model of peripheral T‐cell lymphoma GATA3 reveals DNA damage response pathway vulnerability 2022 ·EMBO Molecular Medicine ·Elizabeth A. Kuczynski, Giulia Morlino, (unknown), Anna Coenen-Stass, (unknown), Neha Wali, Oona Delpuech, (unknown), Anisha Solanki, Charles Sinclair, Dinis Pedro Calado, Larissa S. Carnevalli	5
3	Abstract 1293: AZD0171 (anti-LIF) combines productively with chemotherapy and anti-PD-L1 in mouse models of cancer 2022 ·Cancer Research ·Juliana Candido, Gozde Kar, (unknown), (unknown), (unknown), Elizabeth A. Kuczynski, (unknown), (unknown), (unknown), Nadia Luheshi, Jim Eyles	1
4	Vessel co-option and resistance to anti-angiogenic therapy 2019 ·Angiogenesis ·Elizabeth A. Kuczynski, Andrew R. Reynolds	96
5	Vessel co-option in cancer breakdown → 2019 ·Nature Reviews Clinical Oncology ·Elizabeth A. Kuczynski, Peter Vermeulen, Francesco Pezzella, Robert S. Kerbel, Andrew R. Reynolds	311
6	Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors 2018 ·Molecular Cancer Therapeutics ·Elizabeth A. Kuczynski, Janna Krueger, Annabelle Chow, Ping Xu, Shan Man, Yogi Sundaravadanam, Jessica K. Miller, Paul M. Krzyzanowski, Robert S. Kerbel	20
7	Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity 2018 ·OncoImmunology ·Sophie Langdon, Adina Hughes, Molly A. Taylor, Elizabeth A. Kuczynski, Deanna A. Mele, Oona Delpuech, (unknown), Anna D. Staniszewska, Sabina Cosulich, Larissa S. Carnevalli, Charles Sinclair	40
8	Non-angiogenic tumours and their influence on cancer biology 2018 ·Nature reviews. Cancer ·Tom Dønnem, Andrew R. Reynolds, Elizabeth A. Kuczynski, Kevin C. Gatter, Peter Vermeulen, Robert S. Kerbel, Adrian L. Harris, Francesco Pezzella	108
9	Release of endothelial cell associated VEGFR2 during TGF-β modulated angiogenesis in vitro 2017 ·BMC Cell Biology ·(unknown), Elizabeth A. Kuczynski, Jodi Morrison, Alicia Viloria‐Petit, Brenda L. Coomber	48
10	Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma 2016 ·Chinese Journal of Cancer ·Elizabeth A. Kuczynski, Robert S. Kerbel	21
11	Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma 2016 ·JNCI Journal of the National Cancer Institute ·Elizabeth A. Kuczynski, Melissa Yin, Avinoam Bar‐Zion, Christina R. Lee, Henriett Butz, Shan Man, Frances Daley, Peter Vermeulen, George M. Yousef, F. Stuart Foster, Andrew R. Reynolds, Robert S. Kerbel	125
12	Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma 2015 ·Cancer Research ·Elizabeth A. Kuczynski, Christina R. Lee, Shan Man, Eric X. Chen, Robert S. Kerbel	72
13	Drug rechallenge and treatment beyond progression—implications for drug resistance 2013 ·Nature Reviews Clinical Oncology ·Elizabeth A. Kuczynski, Daniel J. Sargent, Axel Grothey, Robert S. Kerbel	218
14	Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2 2011 ·Cancer ·Elizabeth A. Kuczynski, Alicia Viloria‐Petit, Brenda L. Coomber	10
15	VEGFR2 Expression and TGF-β Signaling in Initial and Recurrent High-Grade Human Glioma 2011 ·Oncology ·Elizabeth A. Kuczynski, (unknown), Brenda L. Coomber	24
16	Feline programmed death and its ligand: Characterization and changes with feline immunodeficiency virus infection 2009 ·Veterinary Immunology and Immunopathology ·(unknown), Xue Wen, Elizabeth A. Kuczynski, Mary E. Clark, Dorothee Bienzle	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact